Browse Studies — Arctuva

Phase 1

A Phase 1a/1b Open Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of JUR-003 in Adult Patients With Metastatic Prostate Cancer

JUR-003-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary anti-…

Metastatic Castration Resistant Prostate CancerOligometastatic Prostate Cancer (OMPC)Metastatic Hormone Sensitive Prostate Cancer

Estimated

~$10 – $8,750

Juri Biosciences, Inc.NCT07824349

Phase 3

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)

This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamid…

Metastatic Castration Sensitive Prostate Cancer (mCSPC)Hormone Sensitive Prostate CancerProstate Cancer+1 more

Estimated

~$10 – $7,500

PfizerNCT07028853

Phase 2

A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants With Advanced Prostate Cancer

Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone…

Prostate CancerMetastatic Castration-Resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer

Estimated

~$10 – $8,750

Astellas Pharma Global Development, Inc.NCT07005154

Phase 2

A Phase II Trial of PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer - The OCEAN Trial

The purpose of this prostate cancer research study is to learn about: 1. Improving control of prostate cancer using radiation therapy, delivered to the para-a…

Prostate CancerProstate AdenocarcinomaHormone Sensitive Prostate Cancer

Estimated

~$10 – $6,250

University of MiamiNCT06392295